In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The closing price of Coherus Biosciences Inc (NASDAQ: CHRS) was $2.25 for the day, up 1.35% from the previous closing price of $2.22. In other words, the price has increased by $1.35 from its previous closing price. On the day, 0.66 million shares were traded. CHRS stock price reached its highest trading level at $2.27 during the session, while it also had its lowest trading level at $2.19.
Ratios:
Our analysis of CHRS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.24 and its Current Ratio is at 1.43.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on November 17, 2023, initiated with a Outperform rating and assigned the stock a target price of $11.
On July 24, 2023, Citigroup started tracking the stock assigning a Buy rating and target price of $12.Citigroup initiated its Buy rating on July 24, 2023, with a $12 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 22 ’23 when Lanfear Dennis M sold 223,100 shares for $2.02 per share. The transaction valued at 449,770 led to the insider holds 731,693 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CHRS now has a Market Capitalization of 255370496 and an Enterprise Value of 616701568. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.99. Its current Enterprise Value per Revenue stands at 2.397 whereas that against EBITDA is -3.256.
Stock Price History:
Over the past 52 weeks, CHRS has reached a high of $8.22, while it has fallen to a 52-week low of $1.43. The 50-Day Moving Average of the stock is -1.01%, while the 200-Day Moving Average is calculated to be -26.11%.
Shares Statistics:
CHRS traded an average of 2.36M shares per day over the past three months and 1230930 shares per day over the past ten days. A total of 112.22M shares are outstanding, with a floating share count of 111.29M. Insiders hold about 1.94% of the company’s shares, while institutions hold 71.76% stake in the company. Shares short for CHRS as of 1713139200 were 21533726 with a Short Ratio of 9.12, compared to 1710460800 on 25912476. Therefore, it implies a Short% of Shares Outstanding of 21533726 and a Short% of Float of 22.2.
Earnings Estimates
At present, 5.0 analysts are actively evaluating the performance of Coherus Biosciences Inc (CHRS) in the stock market.On average, analysts expect EPS of -$0.24 for the current quarter, with a high estimate of -$0.05 and a low estimate of -$0.37, while EPS last year was -$0.75. The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.04 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$0.41 and -$0.96 for the fiscal current year, implying an average EPS of -$0.78. EPS for the following year is $0.04, with 5.0 analysts recommending between $0.68 and -$0.57.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $102M to a low estimate of $47.07M. As of the current estimate, Coherus Biosciences Inc’s year-ago sales were $47.44MFor the next quarter, 6 analysts are estimating revenue of $53.68M. There is a high estimate of $68M for the next quarter, whereas the lowest estimate is $49.56M.
A total of 8 analysts have provided revenue estimates for CHRS’s current fiscal year. The highest revenue estimate was $411M, while the lowest revenue estimate was $206.49M, resulting in an average revenue estimate of $280.31M. In the same quarter a year ago, actual revenue was $257.24MBased on 8 analysts’ estimates, the company’s revenue will be $367.73M in the next fiscal year. The high estimate is $513.75M and the low estimate is $279.91M.
